Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
NCT01480817
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class
Stopped
Difficulty of participant enrollment.
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Sorafenib
PROCEDURE:
TACE for HCC with portal vein invasion
Sponsor
Seoul National University Hospital